This mechanism driven combination may be effective not just in uterine but potentially in TP53 mutant ovarian cancer as well, where Alisertib has been tested as a single agent or in combination with paclitaxel with some success [39]. The gene discussed is TP53; the disease is ovarian carcinoma.